<p><strong>Immix Biopharma Inc</strong> (NASDAQ: IMMX) 的股票在週一早晨略微下跌，此前該臨牀階段生物技術公司向美國證券交易委員會提交了一份新的 S-3 表格的貨架註冊聲明。</p>
<p>該註冊聲明將允許公司不時提供和出售高達 7.5 億美元的普通股、優先股、債務證券、認股權證和單位。</p>
<ul>
<li>Immix Biopharma 股票面臨賣壓。為什麼 IMMX 股票下跌？</li>
</ul>
<h3>新的 7.5 億美元 IMMX 貨架替代 2023 年註冊</h3>
<p>最新的 S-3 結構為根據 SEC 規則 415(a)(6) 的替代貨架，延續了 2023 年 1 月生效的先前註冊中未售出的證券。</p>
<p>根據新的貨架註冊，Immix 可以有機會進入資本市場，未來任何發行的具體條款和定價將在後續的招股説明書補充中詳細説明。</p>
<h3>收益將用於資助 AL 澱粉樣變 CAR-T 管線</h3>
<p>Immix Biopharma 計劃將淨收益主要用於營運資金和一般企業用途，這可能包括推進其主要 CAR-T 候選藥物 NXC-201 用於 AL 澱粉樣變和其他嚴重疾病。</p>
<p>該公司還強調了標準風險因素和前瞻性聲明披露，提醒投資者，任何未來在貨架下的股權發行可能會稀釋現有股東的權益。</p>
<p><strong>Benzinga Edge 排名：</strong> Benzinga Edge 的 專有排名顯示，Immix Biopharma 的動量得分為 96.03，得益於積極的短期、中期和長期價格趨勢。</p>
<p><img src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png"/></p>
<p><strong>IMMX 價格走勢：</strong> 根據 Benzinga Pro 的數據，Immix Biopharma 的股票在週一發佈時下跌了 4.11%，報 4.67 美元。</p>
<h2>Immix Biopharma 能否突破 5 美元關口？</h2>
<p>該股票的 52 周範圍為 1.34 美元至 7.73 美元，突顯了其波動性和顯著的價格波動潛力。目前，價格遠高於該範圍的下限，這可能為希望進入或增加持倉的投資者提供心理支撐位。</p>
<p>在 5.00 美元附近可能會遇到阻力，賣方可能會出現以利用任何上行動能。如果股票能夠突破這一阻力，可能為測試更高水平鋪平道路，潛在接近最近的高點 7.73 美元。</p>
<p>對 Immix Biopharma 的整體技術前景保持謹慎樂觀，因為該股票的交易價格遠高於歷史低點。持續監測成交量和價格走勢將對評估任何潛在反彈或近期進一步下跌的力度至關重要。</p>
<p><em>圖片來源：Shutterstock</em></p>

IMMX

<p>Immix Biopharma Inc（納斯達克代碼：IMMX）股價下跌 4.11%，至 4.67 美元，此前該公司提交了一份新的貨架註冊聲明，計劃發行和出售最多 7.5 億美元的證券。該文件允許 Immix 有機會進入資本市場，主要用於資助其針對 AL 澱粉樣變的 CAR-T 管線。該股票的 52 周區間為 1.34 美元至 7.73 美元，顯示出波動性，阻力位約在 5.00 美元。技術前景保持謹慎樂觀，但投資者應密切關注成交量和價格走勢</p>

<p><strong>Immix Biopharma Inc</strong> (NASDAQ: IMMX) shares are trading marginally lower Monday morning after the clinical-stage biotech filed a new shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p><strong>Immix Biopharma Inc</strong> (NASDAQ: IMMX) 的股票在週一早晨略微下跌，此前該臨牀階段生物技術公司向美國證券交易委員會提交了一份新的 S-3 表格的貨架註冊聲明。</p>
</div><p>The filing would allow the company to offer and sell up to $750 million of common stock, preferred stock, debt securities, warrants and units from time to time.</p>
<div class="lb-trans"><p>該註冊聲明將允許公司不時提供和出售高達 7.5 億美元的普通股、優先股、債務證券、認股權證和單位。</p>
</div><ul>
<li>Immix Biopharma stock is under selling pressure. Why is IMMX stock retreating?</li>
</ul>
<div class="lb-trans"><ul>
<li>Immix Biopharma 股票面臨賣壓。為什麼 IMMX 股票下跌？</li>
</ul>
</div><h3>New $750 Million IMMX Shelf Replaces 2023 Registration</h3>
<div class="lb-trans"><h3>新的 7.5 億美元 IMMX 貨架替代 2023 年註冊</h3>
</div><p>The latest S-3 is structured as a replacement shelf under SEC Rule 415(a)(6), carrying forward unsold securities from a prior registration that was declared effective in January 2023.</p>
<div class="lb-trans"><p>最新的 S-3 結構為根據 SEC 規則 415(a)(6) 的替代貨架，延續了 2023 年 1 月生效的先前註冊中未售出的證券。</p>
</div><p>Under the new shelf registration, Immix can access the capital markets opportunistically, with specific terms and pricing of any future offerings to be detailed in subsequent prospectus supplements.</p>
<div class="lb-trans"><p>根據新的貨架註冊，Immix 可以有機會進入資本市場，未來任何發行的具體條款和定價將在後續的招股説明書補充中詳細説明。</p>
</div><h3>Proceeds to Fund CAR-T Pipeline in AL Amyloidosis</h3>
<div class="lb-trans"><h3>收益將用於資助 AL 澱粉樣變 CAR-T 管線</h3>
</div><p>Immix Biopharma plans to use net proceeds primarily for working capital and general corporate purposes, which may include advancing its lead CAR-T candidate NXC-201 for AL amyloidosis and other serious diseases.</p>
<div class="lb-trans"><p>Immix Biopharma 計劃將淨收益主要用於營運資金和一般企業用途，這可能包括推進其主要 CAR-T 候選藥物 NXC-201 用於 AL 澱粉樣變和其他嚴重疾病。</p>
</div><p>The company also highlighted standard risk factors and forward-looking statement disclosures, reminding investors that any future equity issuance under the shelf could dilute existing shareholders.</p>
<div class="lb-trans"><p>該公司還強調了標準風險因素和前瞻性聲明披露，提醒投資者，任何未來在貨架下的股權發行可能會稀釋現有股東的權益。</p>
</div><p><strong>Benzinga Edge Rankings:</strong> Benzinga Edge's proprietary rankings show Immix Biopharma with a strong Momentum score of 96.03, supported by positive short-, medium- and long-term price trends.</p>
<div class="lb-trans"><p><strong>Benzinga Edge 排名：</strong> Benzinga Edge 的 專有排名顯示，Immix Biopharma 的動量得分為 96.03，得益於積極的短期、中期和長期價格趨勢。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png" alt="" original-src="https://editorial-assets.benzinga.com/wp-content/uploads/2026/01/12100025/Screen-Shot-2026-01-12-at-9.59.57-AM-1024x207.png"/></p>
<p><strong>IMMX Price Action:</strong> Immix Biopharma shares were down 4.11% at $4.67 at the time of publication on Monday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>IMMX 價格走勢：</strong> 根據 Benzinga Pro 的數據，Immix Biopharma 的股票在週一發佈時下跌了 4.11%，報 4.67 美元。</p>
</div><h2>Can Immix Biopharma Break The $5 Barrier?</h2>
<div class="lb-trans"><h2>Immix Biopharma 能否突破 5 美元關口？</h2>
</div><p>The stock’s 52-week range of $1.34 to $7.73 highlights its volatility and potential for significant price swings. Currently, the price is well above the lower end of this range, which may provide a psychological support level for investors looking to enter or add to their positions.</p>
<div class="lb-trans"><p>該股票的 52 周範圍為 1.34 美元至 7.73 美元，突顯了其波動性和顯著的價格波動潛力。目前，價格遠高於該範圍的下限，這可能為希望進入或增加持倉的投資者提供心理支撐位。</p>
</div><p>Resistance is likely to be encountered around the $5.00 mark, where sellers may emerge to capitalize on any upward momentum. Should the stock manage to break through this resistance, it could pave the way for a test of higher levels, potentially approaching the recent highs near $7.73.</p>
<div class="lb-trans"><p>在 5.00 美元附近可能會遇到阻力，賣方可能會出現以利用任何上行動能。如果股票能夠突破這一阻力，可能為測試更高水平鋪平道路，潛在接近最近的高點 7.73 美元。</p>
</div><p>The overall technical outlook for Immix Biopharma remains cautiously optimistic, as the stock is trading well above its historical lows. Continued monitoring of volume and price action will be essential to gauge the strength of any potential recovery or further declines in the near term.</p>
<div class="lb-trans"><p>對 Immix Biopharma 的整體技術前景保持謹慎樂觀，因為該股票的交易價格遠高於歷史低點。持續監測成交量和價格走勢將對評估任何潛在反彈或近期進一步下跌的力度至關重要。</p>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源：Shutterstock</em></p>
</div>

Immix Biopharma (IMMX) 股價下跌，因投資者關注其計劃發行和出售 7.5 億美元的證券